News | December 05, 2023
AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The CAPSUL solution enables optimal process performance for production of premier quality PCL grades at competitive rates
The product has been in-licensed from Strides and will be commercialized by Amneal
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Subscribe To Our Newsletter & Stay Updated
